BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2026-10

220 industry Phase 2/3 trial readout(s) and 44 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2026-09 | 2026-11 →

FDA decision events

DateEventStatusCompanyDrugSource
2026-10-01FDA AdComheldAdCom 2026-10-01: Vaccines and Related Biological Products Advisory Committee
2026-10-01FDA approvalapprovedEVERTRABECTEDINApproved 2026-10-01: TRABECTEDIN (NDA219617 ORIG1)
2026-10-02FDA approvalapprovedLOXO ONCOLJAYPIRCAApproved 2026-10-02: JAYPIRCA (NDA216059 SUPPL6)
2026-10-06FDA approvalapprovedNOVARTIS NVSRHAPSIDOApproved 2026-10-06: RHAPSIDO (NDA218436 SUPPL1)
2026-10-07FDA approvalapprovedSEAGENTUKYSAApproved 2026-10-07: TUKYSA (NDA213411 SUPPL10)
2026-10-08FDA approvalapprovedGENENTECH INCTECENTRIQ HYBREZAApproved 2026-10-08: TECENTRIQ HYBREZA (BLA761347 SUPPL11)
2026-10-08FDA approvalapprovedGENENTECH INCTECENTRIQApproved 2026-10-08: TECENTRIQ (BLA761034 SUPPL65)
2026-10-08FDA approvalapprovedTEVA TEVAWELTRUZAApproved 2026-10-08: WELTRUZA (NDA219007 ORIG1)
2026-10-08FDA approvalapprovedASTRAZENECA AB AZNBREZTRI AEROSPHEREApproved 2026-10-08: BREZTRI AEROSPHERE (NDA220290 ORIG1)
2026-10-09FDA approvalapprovedBRACCOISOVUE READIApproved 2026-10-09: ISOVUE READI (NDA220583 ORIG1)
2026-10-09FDA approvalapprovedAICURIS ANTI-INFECTHOVILPRIApproved 2026-10-09: HOVILPRI (NDA221154 ORIG1)
2026-10-09FDA approvalapprovedELI LILLY AND CO LLYOLUMIANTApproved 2026-10-09: OLUMIANT (NDA207924 SUPPL10)
2026-10-09FDA approvalapprovedAMGEN INC AMGNREPATHAApproved 2026-10-09: REPATHA (BLA125522 SUPPL47)
2026-10-13FDA approvalapprovedVIFOR FRESENIUSVELPHOROApproved 2026-10-13: VELPHORO (NDA205109 SUPPL14)
2026-10-14FDA approvalapprovedALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SUANKTIVAApproved 2026-10-14: ANKTIVA (BLA761336 SUPPL2)
2026-10-14FDA approvalapprovedMERCK SHARP DOHME MRKENFLONSIAApproved 2026-10-14: ENFLONSIA (BLA761432 SUPPL3)
2026-10-15FDA approvalapprovedGENENTECHENSPRYNGApproved 2026-10-15: ENSPRYNG (BLA761149 SUPPL8)
2026-10-15FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2026-10-15: COSENTYX (BLA761349 SUPPL13)
2026-10-15FDA approvalapprovedCOSETTEEVOXACApproved 2026-10-15: EVOXAC (NDA221183 ORIG1)
2026-10-15FDA approvalapprovedUCB INCZILBRYSQApproved 2026-10-15: ZILBRYSQ (NDA216834 SUPPL15)
2026-10-16FDA approvalapprovedBLUEPRINT MEDICINESAYVAKITApproved 2026-10-16: AYVAKIT (NDA212608 SUPPL21)
2026-10-16FDA approvalapprovedFAMYGEN LIFE SCIRYZUMVIApproved 2026-10-16: RYZUMVI (NDA217064 SUPPL5)
2026-10-16FDA approvalapprovedROSEMONT PHARMSYULZETYApproved 2026-10-16: YULZETY (NDA221033 ORIG1)
2026-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-10-16: KEYTRUDA (BLA125514 SUPPL191)
2026-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-10-16: KEYTRUDA QLEX (BLA761467 SUPPL8)
2026-10-16FDA approvalapprovedALCON LABS INC ALCBRYTLYApproved 2026-10-16: BRYTLY (NDA220341 ORIG1)
2026-10-19FDA approvalapprovedGLAXOSMITHKLINEJEMPERLIApproved 2026-10-19: JEMPERLI (BLA761174 SUPPL15)
2026-10-19FDA approvalapprovedFRESENIUS MEDCL CARECIENBYApproved 2026-10-19: CIENBY (NDA219455 ORIG1)
2026-10-19FDA approvalapprovedFRESENIUS MEDCL CARECALREZDYApproved 2026-10-19: CALREZDY (NDA219456 ORIG1)
2026-10-20FDA approvalapprovedGLAXOSMITHKLINEHIBSAGOApproved 2026-10-20: HIBSAGO (NDA221276 ORIG1)
2026-10-21FDA approvalapprovedALEXION PHARMULTOMIRISApproved 2026-10-21: ULTOMIRIS (BLA761108 SUPPL46)
2026-10-22FDA approvalapprovedAMGEN INC AMGNPAVBLUApproved 2026-10-22: PAVBLU (BLA761298 ORIG2)
2026-10-22FDA approvalapprovedFORMYCON AGAHZANTIVEApproved 2026-10-22: AHZANTIVE (BLA761378 ORIG2)
2026-10-22FDA approvalapprovedSANDOZ INCENZEEVUApproved 2026-10-22: ENZEEVU (BLA761382 ORIG2)
2026-10-23FDA approvalapprovedPHARMACOSMOSMONOFERRICApproved 2026-10-23: MONOFERRIC (NDA208171 SUPPL6)
2026-10-23FDA approvalapprovedNOVO NORDISK INC NVOAWIQLI FLEXTOUCHApproved 2026-10-23: AWIQLI FLEXTOUCH (BLA761326 SUPPL1)
2026-10-23FDA approvalapprovedABBVIE INC ABBVSKYRIZIApproved 2026-10-23: SKYRIZI (BLA761105 SUPPL53)
2026-10-26FDA approvalapprovedPFIZER PFETALZENNAApproved 2026-10-26: TALZENNA (NDA217439 SUPPL4)
2026-10-26FDA approvalapprovedPFIZER PFETALZENNAApproved 2026-10-26: TALZENNA (NDA211651 SUPPL14)
2026-10-27FDA approvalapprovedXBRANE BIOPHARMA ABLUCAMZIApproved 2026-10-27: LUCAMZI (BLA761187 ORIG1)
2026-10-29FDA approvalapprovedAVYXA HOLDINGSAXYCISApproved 2026-10-29: AXYCIS (NDA220748 ORIG1)
2026-10-29FDA approvalapprovedSUN PHARMA GLOBALILUMYAApproved 2026-10-29: ILUMYA (BLA761067 SUPPL31)
2026-10-30FDA AdComheldSydnexisAdCom 2026-10-30: Dermatologic and Ophthalmic Drugs Advisory Committee - NDA 219694
2026-10-30PDUFA date (company-disclosed)date passedINOVIO PHARMACEUTICALS, INC. INOPDUFA October 30, 2026 - INOVIO PHARMACEUTICALS, INC.

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P1/P2Sernova Biotherapeutics Inc.NCT03513939 A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet TransplantationType 1 Diabetes Mellitusactive not recruiting17
2026-10 est.P3Eli Lilly and Company LLYNCT04088396 A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Systemic Juvenile Idiopathic Arthritisactive not recruiting58
2026-10 est.P1/P2Immunocore Ltd IMCRNCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsSelect Advanced Solid Tumorsactive not recruiting410
2026-10 est.P2Vyriad, Inc.NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsMelanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Canceractive not recruiting87
2026-10 est.P1/P2Laminar PharmaceuticalsNCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid TumorsHigh-grade Glioma; Solid Tumor, Unspecified, Childrecruiting28
2026-10 est.P1/P2Philogen S.p.A.NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomarecruiting226
2026-10 est.P3Inmunotek S.L.NCT04898283 Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergicrecruiting180
2026-10 est.P1/P2Wave Life Sciences USA, Inc. WVENCT04906460 Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)Duchenne Muscular Dystrophyactive not recruiting25
2026-10 est.P3Loxo Oncology, Inc.NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting600
2026-10 est.P2Gilead Sciences GILDNCT05119907 Study of Sacituzumab Govitecan in Patients With Solid TumorSolid Tumoractive not recruiting53
2026-10 est.P2Corcept Therapeutics CORTNCT05407324 Dazucorilant in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosisactive not recruiting279
2026-10 est.P3AbbVie ABBVNCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNVactive not recruiting735
2026-10 est.P3GIE MedicalNCT05561114 Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- EsophagusEsophageal Stricturerecruiting198
2026-10 est.P2GEn1E LifesciencesNCT05795465 A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)Respiratory Distress Syndrome, Acuterecruiting52
2026-10 est.P3Industrial Farmacéutica Cantabria, S.A.NCT05888922 Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic AlopeciaAndrogenetic Alopecia; Female Pattern Baldnessactive not recruiting520
2026-10 est.P2/P3Privo TechnologiesNCT05893888 A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung CancersOral Squamous Cell Carcinomarecruiting40
2026-10 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06057922 A Study YL201 in Patients With Selected Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting990
2026-10 est.P3Curium US LLCNCT06235151 Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerProstate Cancer; Prostate Adenocarcinomaactive not recruiting439
2026-10 est.P1/P2RinuaGene Biotechnology Co., Ltd.NCT06273553 A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3Human Papillomavirus Associated Intraepithelial Neoplasia; Cervical Intraepithelial Neoplasia Grade not yet recruiting39
2026-10 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Non Small Cell Lung Cancerrecruiting522
2026-10 est.P2/P3Biohaven Therapeutics Ltd. BHVNNCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyFocal Epilepsyactive not recruiting390
2026-10 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerHER2-positive Breast Canceractive not recruiting274
2026-10 est.P3Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.NCT06403501 Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisAcne Vulgarisrecruiting692
2026-10 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarHER2-positive Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting64
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474468 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal CancerAdvanced or Metastatic Esophageal Cancerunknown148
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerAdvanced or Metastatic Non-small Cell Lung Cancerrecruiting248
2026-10 est.P1/P2CanSino Biologics Inc.NCT06577298 A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and ToddlersPoliomyelitisactive not recruiting480
2026-10 est.P1/P2Biotheus Inc.NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCHCC; Liver Cancernot yet recruiting140
2026-10 est.P3AkesoNCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting682
2026-10 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06598787 A Study of BL-B01D1 in Patients With Recurrent GlioblastomaRecurrent Glioblastomarecruiting20
2026-10 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Advanced Hepatocellular Carcinomarecruiting590
2026-10 est.P1/P2Nimble Science Ltd.NCT06702280 Assessing the Safety of an IGY Supplement on the Gut MicrobiomeHealthy; Microbiomewithdrawn
2026-10 est.P2Keymed Biosciences Co.LtdNCT06791772 Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Systemic Lupus Erythematosusnot yet recruiting150
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-10 est.P2/P3Ebima Clifford OkundayeNCT06866236 Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionChronic Kidney Diseases; Acute Kidney Injury; Kidney Failurenot yet recruiting3000
2026-10 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibiHR+/HER2- Advanced/Metastatic Breast Cancernot yet recruiting312
2026-10 est.P2Immunovant Sciences GmbH IMVTNCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosusactive not recruiting56
2026-10 est.P2Vanda Pharmaceuticals VNDANCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionHypertension; Uncontrolled Hypertensionrecruiting240
2026-10 est.P1/P2TYK Medicines, IncNCT07104617 Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)Metastatic Castration-resistant Prostate Cancer (mCRPC)not yet recruiting48
2026-10 est.P2ImmunityBio, Inc. IBRXNCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19.Long COVIDrecruiting20
2026-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerCLDN18.2-positive Advanced Biliary Tract Cancernot yet recruiting120
2026-10 est.P2Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.NCT07159243 Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic Painnot yet recruiting180
2026-10 est.P2Triveni BioNCT07167758 A Study Evaluating TRIV-509 in Atopic DermatitisAtopic Dermatitisactive not recruiting95
2026-10 est.P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNon-small Cell Lung Cancerrecruiting300
2026-10 est.P1/P2Shanghai Shengdi Pharmaceutical Co., LtdNCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsSolid Tumorsrecruiting258
2026-10 est.P2Lallemand Health SolutionsNCT07246161 Vaginal Detection of Orally Delivered Probiotic Strains in Healthy WomenFocus is on Healthy Subjectsrecruiting72
2026-10 est.P2Advagene Biopharma Co. Ltd.NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaEosinophilic Asthmanot yet recruiting126
2026-10 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting444
2026-10 est.P3Senseye, Inc.NCT07280065 REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic ToolPTSD - Post Traumatic Stress Disorderrecruiting1900
2026-10 est.P1/P2Aramis Biotechnologies Inc.NCT07291635 Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza VaccineInfluenzaactive not recruiting728
2026-10 est.P2Beijing Inno Medicine Co., Ltd.NCT07311330 Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile DysfunctionAtherosclerotic Cardiovascular Disease (ASCVD); Erectile Dysfunctionrecruiting40
2026-10 est.P2Disc Medicine, Inc IRONNCT07368972 Study of DISC-0974-201 in Participants With IBD and AnemiaInflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemiarecruiting21
2026-10 est.P2Housey Healthcare ULCNCT07546929 HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 DiabetesType 2 Diabetesrecruiting300
2026-10 est.P2Chengdu Kangnuoxing Biopharma,Inc.NCT07617324 Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Seasonal Allergic Rhinitis (SAR)not yet recruiting15
2026-10 est.P3Colgate Palmolive CLNCT07625670 Clinical Study to Evaluate Remineralization Using an in Situ Model.Remineralization; Enamel Lesions; Enamel Subsurface Lesionenrolling by invitation30
2026-10 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07640451 A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCOPDrecruiting90
2026-10 est.P2/P3Shanghai Huilun Pharmaceutical Co., Ltd.NCT07699601 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic SurgeryPostoperative Painrecruiting330
2026-10 est.P2Shandong Suncadia Medicine Co., Ltd.NCT07706777 Clinical Study of HRS-2129 for Acute Gouty ArthritisAcute Gouty Arthritisrecruiting90
2026-10 est.P2/P3Shanghai Huilun Pharmaceutical Co., Ltd.NCT07709598 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal SurgeryPostoperative Painrecruiting330
2026-10 est.P2AbbVie ABBVNCT07730554 A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsForehead Linesactive not recruiting84
2026-10 est.P2Shanghai Minwei Biotechnology Co., LtdNCT07791537 Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightOverweight , Obesityactive not recruiting125
2026-10 est.P2Taejoon Pharmaceutical Co., Ltd.NCT07810972 Evaluate the Safety and Efficacy of TJO-087Dry Eye Syndrome (DES)active not recruiting90
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10-01 est.P1/P2USWM CT, LLCNCT05642455 SPEARHEAD-3 Pediatric StudySynovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcomarecruiting20
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10-01 est.P3Novo Nordisk A/S NVONCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationHeart Failure; Systemic Inflammationactive not recruiting673
2026-10-01 est.P3Beijing Dongfang Biotech Co., Ltd.NCT06257966 A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminType2 Diabetes Mellitusactive not recruiting600
2026-10-01P2Incyte Corporation INCYNCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseactive not recruiting130
2026-10-01 est.P2RemeGen Co., Ltd.NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerBreast Cancerrecruiting40
2026-10-01 est.P1/P2KelifarmaNCT06678399 Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal CellPreemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgerynot yet recruiting91
2026-10-01 est.P1/P2Inhatarget TherapeuticsNCT06896890 Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung CancerNSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancerrecruiting32
2026-10-01P3Incyte Corporation INCYNCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Hidradenitis Suppurativaactive not recruiting573
2026-10-01P2Nuvig Therapeutics, Inc.NCT07027111 Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDPChronic Inflammatory Demyelinating Polyneuropathyterminated14
2026-10-01 est.P2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07188610 PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaCD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphomarecruiting100
2026-10-01 est.P1/P2Prana Therapies IncNCT07245368 Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate AsthmaMild to Moderate Asthmarecruiting96
2026-10-01P2Qlaris Bio, Inc.NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel DilationNon-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (Ncompleted9
2026-10-01 est.P2Research Institute of Geroprotective TechnologiesNCT07397351 Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent ImplantationCoronary Artery Diseaserecruiting180
2026-10-01 est.P2BioRay Pharmaceutical Co., Ltd.NCT07498647 Clinical Trial of BR2251 Tablets for Patients With Primary Gout and HyperuricemiaGout and Hyperuricemianot yet recruiting160
2026-10-01 est.P2Fujian Akeylink Biotechnology Co., Ltd.NCT07709520 Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis BChronic Hepatitis Brecruiting80
2026-10-01P1/P2AstraZeneca AZNNCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)RSV Respiratory Syncytial Virusactive not recruiting164
2026-10-02P3SK Life Science, Inc.NCT05067634 Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPartial Epilepsycompleted154
2026-10-02P3MedTrace Pharma A/SNCT05134012 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)Coronary Artery Diseasecompleted232
2026-10-02 est.P1/P2PEACHES BIOTECHNCT06684379 Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-CoSARS-CoV-2; Influenza, Human; Respiratory Syncytial Virus Infections; Respiratory Distress Syndrome;recruiting50
2026-10-02P2Teva Branded Pharmaceutical Products R&D LLCNCT06807463 A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseCeliac Diseaseactive not recruiting50
2026-10-04P2Bausch & Lomb Incorporated BLCONCT07412496 A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive KeratectomyPain, Postoperativecompleted130
2026-10-04 est.P2Eddingpharm (Zhuhai) Co., Ltd.NCT07489209 A Dose-exploration Study of EDP167 in HoFHHomozygous Familial Hypercholesterolemia (HoFH)recruiting20
2026-10-05 est.P3Swedish Orphan BiovitrumNCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibactive not recruiting407
2026-10-05 est.P1/P2ModernaTX, Inc.NCT05164094 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsEpstein-Barr Virus Infectionactive not recruiting867
2026-10-05 est.P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Psychosis Associated With Alzheimer's Diseaserecruiting410
2026-10-05P2Hoffmann-La RocheNCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomRenal Cell Carcinomacompleted199
2026-10-05P2/P3UCB Biopharma SRLNCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted14
2026-10-05P2Ferrer Internacional S.A.NCT06355531 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsycompleted241
2026-10-06P3GlaxoSmithKlineNCT05263934 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Eosinophilic Granulomatosis With Polyangiitiscompleted163
2026-10-06P1/P2Pfizer PFENCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-StBreast Cancerterminated20
2026-10-06P3ArriVent BioPharma, Inc. AVBPNCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EpidermalMetastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutationsactive not recruiting398
2026-10-06 est.P3Bristol-Myers Squibb BMYNCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisactive not recruiting1255
2026-10-07P1/P2ModernaTX, Inc.NCT05992935 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 8Norovirus Acute Gastroenteritiscompleted1407
2026-10-08 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07163364 A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)Methylmalonic Acidemia (MMA)not yet recruiting20
2026-10-09P3Regeneron Pharmaceuticals REGNNCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Atopic Dermatitiscompleted880
2026-10-09P3Debiopharm International SANCT06129539 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)Central Precocious Pubertyactive not recruiting56
2026-10-09P2Xentria, Inc.NCT06169397 An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary SarcoidosisPulmonary Sarcoidosiscompleted31
2026-10-09P2Pfizer PFENCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical StuPulmonary Hypertensionterminated42
2026-10-10 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07193459 Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes MellitusType 2 Diabetesrecruiting360
2026-10-10P1/P2Chongqing Peg-Bio Biopharm Co., Ltd.NCT07446491 A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedureThrombocytopenia Associated With Chronic Liver Diseasecompleted54
2026-10-11 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07083505 A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast CancerAdvanced Breast Cancernot yet recruiting60
2026-10-11 est.P3BiocodexNCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel SyndromeIBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptomsrecruiting406
2026-10-12 est.P1/P2Bristol-Myers Squibb BMYNCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or RefractMultiple Myelomarecruiting260
2026-10-12 est.P3Janssen Research & Development, LLCNCT05884398 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCMetastatic Castrate-sensitive Prostate Canceractive not recruiting420
2026-10-12 est.P2Jiangsu Carephar Pharmaceutical Co., Ltd.NCT07677514 A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's DiseaseCrohn's Diseasenot yet recruiting156
2026-10-13P2AbbVie ABBVNCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD)active not recruiting146
2026-10-13 est.P1/P2Aspa TherapeuticsNCT04998396 A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)Canavan Diseaserecruiting26
2026-10-13 est.P2Daewoong Pharmaceutical Co. LTD.NCT05389215 Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFIdiopathic Pulmonary Fibrosisactive not recruiting102
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10-13 est.P3Shanghai JMT-Bio Inc.NCT06846437 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerUnrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participantsrecruiting228
2026-10-13P1/P2Voyager Therapeutics VYGRNCT06874621 VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseAlzheimer&#39;s Disease (AD)active not recruiting52
2026-10-14 est.P3Hoffmann-La RocheNCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BUnresectable Hepatocellular Carcinomaactive not recruiting557
2026-10-14P3Organon and Co OGNNCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsPlaque Psoriasiscompleted58
2026-10-15 est.P3Janssen Research & Development, LLCNCT05702034 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEIschemic Stroke; Ischemic Attack, Transientactive not recruiting12523
2026-10-15P2Hoffmann-La RocheNCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-AdvancedBreast Cancercompleted83
2026-10-15P3Novartis Pharmaceuticals NVSNCT05900141 An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Hyperlipoproteinemia (a)terminated41
2026-10-15 est.P1/P2Eclipse Life Sciences, Inc.NCT06536491 EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaDiabetic Macular Edemaactive not recruiting75
2026-10-15 est.P3Suzhou Alphamab Co., Ltd.NCT06569108 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsHemophilia A Without Inhibitor; Hemophilia B Without Inhibitoractive not recruiting125
2026-10-15 est.P2EccogeneNCT07505303 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialAdult Obesity; Weight Managementactive not recruiting151
2026-10-15P3Dexa Medica GroupNCT07937449 The Efficacy and Safety of DLBS3233 in Adults With PrediabetesPrediabetescompleted120
2026-10-16P3LEO PharmaNCT06311682 A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DAtopic Dermatitisrecruiting195
2026-10-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairNCT07033585 Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled CancersType 2 Diabetesactive not recruiting600
2026-10-18 est.P2Kunming Pharmaceuticals, Inc.NCT07279493 Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic StrokeAcute Ischemic Strokerecruiting300
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosusactive not recruiting516
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting513
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-10-19 est.P3Incyte Corporation INCYNCT06516952 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Prurigo Nodularisactive not recruiting349
2026-10-19P1/P2Arsenal Biosciences, Inc.NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)terminated3
2026-10-20 est.P2/P3Biogen BIIBNCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosusactive not recruiting450
2026-10-20 est.P1/P2Bioray LaboratoriesNCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaBeta-Thalassemiaactive not recruiting39
2026-10-20 est.P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06894212 A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaSchizophreniaactive not recruiting538
2026-10-21P2Oruka Therapeutics, Inc. ORKANCT07290569 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting160
2026-10-21P3Vaxcyte, Inc. PCVXNCT07365826 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgePneumococcal Diseasecompleted1390
2026-10-22 est.P3Hoffmann-La RocheNCT03523858 A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisProgressive Multiple Sclerosis (PMS)active not recruiting927
2026-10-22P1/P2Hoffmann-La RocheNCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaNon-Hodgkins Lymphomacompleted211
2026-10-22 est.P3Amgen AMGNNCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateSjögren's Syndrome (SS)active not recruiting434
2026-10-22P3Eli Lilly and Company LLYNCT06339008 A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Perennial Allergic Rhinitis (PAR)active not recruiting450
2026-10-22 est.P2Shanghai Henlius BiotechNCT06812260 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLCSCLC, Extensive Stageactive not recruiting26
2026-10-23 est.P3Qilu Pharmaceutical Co., Ltd.NCT06799559 Study on the Efficacy and Safety of QLM1016 in SchizophreniaSchizophreniaactive not recruiting402
2026-10-23 est.P2AstraZeneca AZNNCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightObesity/Overweightactive not recruiting16
2026-10-24P2Clear Scientific, Inc.NCT06721494 A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of MethamphetamineMethamphetamine Intoxication; Methamphetamine Disorders; Methamphetamine Abusecompleted34
2026-10-25P3Vaxcyte, Inc. PCVXNCT07425392 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationPneumococcal Diseasecompleted752
2026-10-26 est.P3Galderma R&DNCT04204616 A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Prurigo Nodularisactive not recruiting500
2026-10-26 est.P3Novartis Pharmaceuticals NVSNCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression inCoronary Artery Diseaseactive not recruiting610
2026-10-26P2GlaxoSmithKlineNCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerLung Cancer, Non-Small Cellactive not recruiting351
2026-10-26P3Eli Lilly and Company LLYNCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on BaType 2 Diabetesactive not recruiting341
2026-10-26P3Teva Branded Pharmaceutical Products R&D LLCNCT06664619 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years andAsthmacompleted649
2026-10-26P2Boehringer IngelheimNCT06722157 A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyMacular Degeneration, Age-related; Geographic Atrophycompleted202
2026-10-27P2Gilead Sciences GILDNCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionChronic Hepatitis Bactive not recruiting150
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-10-27 est.P1/P2Shanghai Huaota Biopharmaceutical Co., Ltd.NCT07449156 A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.Acne Vulgarisnot yet recruiting21
2026-10-28 est.P3Merck Sharp & Dohme LLC MRKNCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post NephrecCarcinoma, Renal Cellactive not recruiting1800
2026-10-28 est.P3Albireo, an Ipsen CompanyNCT05426733 An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaBiliary Atresiaactive not recruiting180
2026-10-28P2Genentech, Inc.NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Chronic Lymphocytic Leukemiaactive not recruiting118
2026-10-28 est.P3AkesoNCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNSCLC (Non-small Cell Lung Cancer)recruiting560
2026-10-28P3Xenon Pharmaceuticals Inc. XENENCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderMajor Depressive Disorderterminated357
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-29P3Novartis Pharmaceuticals NVSNCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)active not recruiting226
2026-10-29 est.P2RECORDATI GROUPNCT05928390 Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaPost-Bariatric Hypoglycemiaactive not recruiting93
2026-10-29P2Acumen Pharmaceuticals ABOSNCT06335173 A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Alzheimer Diseaseactive not recruiting542
2026-10-29 est.P3Hoffmann-La RocheNCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active UlceModerately to Severely Active Ulcerative Colitisactive not recruiting350
2026-10-29P3Incyte Corporation INCYNCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Hidradenitis Suppurativaactive not recruiting580
2026-10-29P2Tisento TherapeuticsNCT06961344 An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)terminated37
2026-10-30 est.P2Genzyme, a Sanofi CompanyNCT02843035 Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1; Gaucher Disease Type 3active not recruiting12
2026-10-30 est.P1/P2Nouscom SRLNCT04041310 Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsSolid Tumor, Adultactive not recruiting115
2026-10-30 est.P3Pfizer PFENCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaMelanomaactive not recruiting257
2026-10-30 est.P3Laekna LimitedNCT04851613 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerBreast Canceractive not recruiting256
2026-10-30 est.P3Vertex Pharmaceuticals Incorporated VERXNCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyCystic Fibrosisactive not recruiting822
2026-10-30 est.P2Mirati Therapeutics Inc.NCT05853575 Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lungactive not recruiting200
2026-10-30 est.P1/P2Biotheus Inc.NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCTNBCactive not recruiting42
2026-10-30 est.P2Abbisko Therapeutics Co, LtdNCT06186804 A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)cGvHDenrolling by invitation64
2026-10-30P3Ultragenyx Pharmaceutical Inc RARENCT06415344 Long-term Extension of GTX-102 in Angelman SyndromeAngelman Syndrometerminated66
2026-10-30 est.P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06679036 A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast Cancerrecruiting300
2026-10-30 est.P1/P2Shanghai Henlius BiotechNCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsSolid Tumor Cancer; Non Small Cell Lung Cancerrecruiting105
2026-10-30 est.P1/P2Antelope Surgical Solutions, IncNCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NSProstate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imagingactive not recruiting15
2026-10-30 est.P1/P2Nuwacell Biotechnologies Co., Ltd.NCT06941350 A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHDAcute Graft-versus-Host Diseasenot yet recruiting24
2026-10-30 est.P2Insud PharmaNCT06968481 Sublingual Oxytocin for the Prevention of Post-partum HemorrhagePost Partum Hemorrhagenot yet recruiting330
2026-10-30P1/P2Arvinas Inc. ARVNNCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationKRAS G12D Mutation; Advanced Solid Cancercompleted76
2026-10-30 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT07026968 A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesType 2 Diabetesactive not recruiting815
2026-10-30 est.P1/P2Vidya Therapeutics IncNCT07085507 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS PatientsMultiple Sclerosisrecruiting100
2026-10-30P2Ultragenyx Pharmaceutical Inc RARENCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Angelman Syndrometerminated55
2026-10-30P2Beijing InnoCare Pharma Tech Co., Ltd.NCT07251998 Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted182
2026-10-30 est.P2Jiangxi Kvvit Pharmaceutical Co., Ltd.NCT07345390 Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne VulgarisAcne Vulgarisnot yet recruiting180
2026-10-30 est.P2Vincentage Pharma Co., LtdNCT07360275 A Study of VCT220 in Participants With Hypertension and Obesity or OverweightHypertensionactive not recruiting160
2026-10-30 est.P3Natureceuticals Sdn BhdNCT07669467 Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast CancerFatigue Related to Cancer Treatment; Breast Cancerrecruiting250
2026-10-31 est.P1/P2Orion Corporation, Orion Pharma ORNNCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerProstate Cancer Metastaticactive not recruiting204
2026-10-31 est.P2Astellas Pharma Global Development, Inc.NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinomaactive not recruiting393
2026-10-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04842617 Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeHormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stageactive not recruiting5274
2026-10-31 est.P1/P2LaNova Medicines LimitedNCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting392
2026-10-31 est.P2AskBio IncNCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureCongestive Heart Failureactive not recruiting150
2026-10-31 est.P1/P2Intralytix, Inc.NCT05715619 Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized SubjectsVancomycin-Resistant Enterococcal Colonizationsuspended80
2026-10-31 est.P2MaaT PharmaNCT05762211 Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)Transplant Complicationrecruiting387
2026-10-31 est.P3Olema Oncology, Inc. OLMANCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerBreast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negactive not recruiting510
2026-10-31 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT06083207 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting116
2026-10-31 est.P2NEXTGEN BioscienceNCT06104839 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia AreataAlopecia Areatarecruiting73
2026-10-31 est.P2Kyowa Kirin Co., Ltd.NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaDiabetic Macular Edema (DME)active not recruiting185
2026-10-31 est.P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06222879 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerBreast Cancerunknown350
2026-10-31 est.P2Salubris Biotherapeutics IncNCT06369298 Study of JK07 in Patients With Chronic Heart FailureHeart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fractionactive not recruiting282
2026-10-31 est.P2Avistone Biotechnology Co., Ltd.NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Non-Small-Cell Lung Cancerrecruiting120
2026-10-31 est.P2Amgen AMGNNCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)MTAP-deleted NSCLCactive not recruiting61
2026-10-31 est.P3AstraZeneca AZNNCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsBreast Canceractive not recruiting293
2026-10-31 est.P3Longboard PharmaceuticalsNCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Developmental and Epileptic Encephalopathyactive not recruiting367
2026-10-31 est.P2Shanghai Henlius BiotechNCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyCarcinoma, Hepatocellularrecruiting90
2026-10-31 est.P2Shanghai Henlius BiotechNCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyEsophageal Cancerrecruiting102
2026-10-31 est.P2Topadur Pharma AGNCT06954597 Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic SclerosisDigital Ulcers in Systemic Sclerosisrecruiting15
2026-10-31 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07019090 Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)not yet recruiting120
2026-10-31 est.P2Animuscure Inc.NCT07072195 A Study of AMC6156 in People With SarcopeniaSarcopenia in Elderly; Sarcopeniarecruiting80
2026-10-31 est.P2Spyre Therapeutics, Inc. SYRENCT07148414 A Study of SPY072 in Rheumatic DiseaseRheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joactive not recruiting285
2026-10-31 est.P1/P2Myosin Therapeutics Inc.NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM PatientsGlioblastoma (GBM)recruiting36
2026-10-31 est.P3TG Therapeutics, Inc. TGTXNCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With RelapsingRelapsing Multiple Sclerosisactive not recruiting360
2026-10-31 est.P2Neurimmune AGNCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMAmyloid Transthyretin Cardiomyopathyactive not recruiting35
2026-10-31 est.P2Changzhou Qianhong Bio-pharma Co., Ltd.NCT07396337 Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.Acute Ischemic Strokerecruiting320
2026-10-31 est.P2Kadence BioNCT07434271 Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong PrPremature Ejaculationrecruiting40
2026-10-31 est.P2Freya Biosciences ApSNCT07453069 Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer CycleVaginal Dysbiosisrecruiting30
2026-10-31 est.P3Natureceuticals Sdn BhdNCT07669454 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule inFatigue Related to Cancer Treatment; Colon Cancerrecruiting250

← 2026-09 | 2026-11 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.